3PBIOVIAN Revenue and Competitors
Estimated Revenue & Valuation
- 3PBIOVIAN's estimated annual revenue is currently $51.7M per year.
- 3PBIOVIAN's estimated revenue per employee is $201,000
Employee Data
- 3PBIOVIAN has 257 Employees.
- 3PBIOVIAN grew their employee count by 527% last year.
3PBIOVIAN's People
Name | Title | Email/Phone |
---|
3PBIOVIAN Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $17.7M | 88 | 7% | N/A | N/A |
#2 | $89.4M | 445 | 9% | N/A | N/A |
#3 | $32.4M | 161 | 25% | N/A | N/A |
#4 | $44.4M | 221 | 7% | N/A | N/A |
#5 | $120.2M | 427 | 17% | $446.2M | N/A |
#6 | $54.3M | 270 | 10% | N/A | N/A |
#7 | $49.6M | 247 | 52% | N/A | N/A |
#8 | $21.9M | 109 | -1% | N/A | N/A |
#9 | $16.5M | 82 | 4% | N/A | N/A |
#10 | $26.7M | 133 | 25% | N/A | N/A |
What Is 3PBIOVIAN?
3PBIOVIAN service offering includes microbial and mammalian protein expression platforms, viral vector production for adenoviruses and adeno-associated viruses, cell therapy, and plasmid DNA production, with the provision for fill and finish services for recombinant proteins and viral vectors. Leveraging a combined track record of 40 years in process development and analytical methods development, complemented by the experience in process scale-up, GMP manufacturing, and commercial supply, 3PBIOVIAN is equipped to offer comprehensive manufacturing services at all stages, encompassing Drug Substance and Drug Product. Manufacturing sites in Pamplona-Noáin, Spain, and Turku, Finland seamlessly support the diverse needs of clients, covering pre-clinical and clinical supply to full-scale commercial manufacturing.
keywords:N/AN/A
Total Funding
257
Number of Employees
$51.7M
Revenue (est)
527%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $41M | 257 | 5% | N/A |
#2 | $42.4M | 257 | 22% | N/A |
#3 | N/A | 258 | 21% | N/A |
#4 | $39.9M | 259 | -11% | N/A |
#5 | $40M | 260 | -8% | $25M |